These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 31116603)

  • 21. Implications of subcutaneous or intravenous delivery of trastuzumab; further insight from patient interviews in the PrefHer study.
    Fallowfield L; Osborne S; Langridge C; Monson K; Kilkerr J; Jenkins V
    Breast; 2015 Apr; 24(2):166-70. PubMed ID: 25623753
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysis.
    Alexander M; Jachno K; Phillips KA; Seymour JF; Slavin MA; Cheung A; Shen V; Maarouf D; Wolfe R; Lingaratnam S
    J Oncol Pharm Pract; 2024 Jun; 30(4):642-660. PubMed ID: 37322897
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study.
    Pivot X; Gligorov J; Müller V; Barrett-Lee P; Verma S; Knoop A; Curigliano G; Semiglazov V; López-Vivanco G; Jenkins V; Scotto N; Osborne S; Fallowfield L;
    Lancet Oncol; 2013 Sep; 14(10):962-70. PubMed ID: 23965225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Subcutaneous administration of trastuzumab at home: Feedback of patients treated in 2016 by Santé service].
    Pailler C; Chapot T; Softa S; Gandrille N; Ruiz D; Mathieu S; Delaloge S
    Bull Cancer; 2018 Dec; 105(12):1126-1134. PubMed ID: 30466957
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subcutaneous versus intravenous administration of trastuzumab: preference of HER2+ breast cancer patients and financial impact of its use.
    Lazaro Cebas A; Cortijo Cascajares S; Pablos Bravo S; Del Puy Goyache Goñi M; Gonzalez Monterrubio G; Perez Cardenas MD; Ferrari Piquero JM
    J BUON; 2017; 22(2):334-339. PubMed ID: 28534353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NICE recommends routine NHS funding for Kadcyla.
    Venkatesa P
    Lancet Oncol; 2017 Aug; 18(8):e435. PubMed ID: 28648556
    [No Abstract]   [Full Text] [Related]  

  • 27. Looking for Her (2+): A systematic review of the economic evaluations of Trastuzumab in early stage HER 2 positive breast cancer.
    Petrou P
    Expert Rev Pharmacoecon Outcomes Res; 2019 Apr; 19(2):115-125. PubMed ID: 30320510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom.
    Rule S; Collins GP; Samanta K
    J Med Econ; 2014 Jul; 17(7):459-68. PubMed ID: 24720836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Flexible care in breast cancer.
    Wardley A; Canon JL; Elsten L; Peña Murillo C; Badovinac Crnjevic T; Fredriksson J; Piccart M
    ESMO Open; 2021 Feb; 6(1):100007. PubMed ID: 33450658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hospital-based or home-based administration of oncology drugs? A micro-costing study comparing healthcare and societal costs of hospital-based and home-based subcutaneous administration of trastuzumab.
    Franken M; Kanters T; Coenen J; de Jong P; Jager A; Groot CU
    Breast; 2020 Aug; 52():71-77. PubMed ID: 32447129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities.
    Bittner B; Richter W; Schmidt J
    BioDrugs; 2018 Oct; 32(5):425-440. PubMed ID: 30043229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer.
    Wynne C; Harvey V; Schwabe C; Waaka D; McIntyre C; Bittner B
    J Clin Pharmacol; 2013 Feb; 53(2):192-201. PubMed ID: 23436264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is the Fixed-Dose Intravenous Trastuzumab Policy Warranted in Limited-Resource Settings?
    Kassem L; Shohdy KS; Abdel-Azeez AM; Attia H
    J Glob Oncol; 2019 Jan; 5():1-3. PubMed ID: 30676841
    [No Abstract]   [Full Text] [Related]  

  • 34. Quality of care in the course of subcutaneous versus intravenous trastuzumab administration in patients with breast cancer: an integrated time-motion study with mixed-methods research.
    Lin HW; Lin CY; Yeh TP; Lin TC; Yeh WC; Yang LC; Chen YC; Chiu LY; Wu CT; Chen CJ; Chen YF; Wang HC; Wu YC; Liu LC
    BMJ Open; 2023 Mar; 13(3):e059288. PubMed ID: 36927581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NICE approves trastuzumab emtansine after deal with drug company.
    Kmietowicz Z
    BMJ; 2017 Jun; 357():j2930. PubMed ID: 28623237
    [No Abstract]   [Full Text] [Related]  

  • 36. The Economic Impact of Biosimilars in Oncology and Hematology: The Case of Trastuzumab and Rituximab.
    Giuliani J; Bonetti A
    Anticancer Res; 2019 Jul; 39(7):3971-3973. PubMed ID: 31262930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trastuzumab biosimilar shows potential for breast cancer.
    Baker H
    Lancet Oncol; 2017 Jan; 18(1):e4. PubMed ID: 27956154
    [No Abstract]   [Full Text] [Related]  

  • 38. Current situation and challenges regarding biosimilars in Japan: an example of trastuzumab biosimilars for breast cancer.
    Hara F; Tajima K; Tanabe K
    Future Oncol; 2019 Apr; 15(12):1353-1361. PubMed ID: 30767568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Trastuzumab and its biosimilars].
    Sarosiek T; Morawski P
    Pol Merkur Lekarski; 2018 May; 44(263):253-257. PubMed ID: 29813044
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PEGylation does not significantly change the initial intravenous or subcutaneous pharmacokinetics or lymphatic exposure of trastuzumab in rats but increases plasma clearance after subcutaneous administration.
    Chan LJ; Bulitta JB; Ascher DB; Haynes JM; McLeod VM; Porter CJ; Williams CC; Kaminskas LM
    Mol Pharm; 2015 Mar; 12(3):794-809. PubMed ID: 25644368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.